IRISH

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Thursday, February 2, 2023

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.